Neurocrine Biosciences (NBIX): Increasingly Bullish on Valbenazine - BMO

October 27, 2016 6:43 AM EDT
Get Alerts NBIX Hot Sheet
Price: $41.27 -0.84%

Rating Summary:
    15 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade NBIX Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on shares of Neurocrine Bio. (NASDAQ: NBIX) and raised his price target to $72 from $66 after hosting investor meetings with NBIX management.

The analyst believes valbenazine could achieve peak sales of $1.8B, up from $1.5B, with positive Tourette's data (adult in January and peds in 1Q17) representing an incremental $700 mm opportunity. We continue to believe that NBIX's current valuation could be supported by either elagolix or valbenazine alone. Both are likely to receive regulatory approval and achieve commercial success and he sees significant potential upside to NBIX shares.

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $44.70 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

BMO Capital

Add Your Comment